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Objective: To describe the pharmacokinetics, safety, and efficacy of twice-daily 
indinavir + ritonavir regimens 
Design: A cohort-based survey of HIV-infected patients who either used indinavir 
800 mg + ritonavir 100 mg twice daily or indinavir 400 mg + ritonavir 400 mg twice 
daily. 
Methods: Data were extracted from a database of samples sent to our laboratory for 
measurement of indinavir + ritonavir plasma concentrations. Patient characteristics, 
safety, and efficacy measurements were collected by retrospective chart review. 
Results: I 00 Patients using 800-mg indinavir + 100-mg ritonavir twice daily and 32 
patients using 400-mg indinavir + 400-mg ritonavir twice daily were eligible. Median 
peak and trough concentrations of indinavir were 6.8 and 0.77 mg/Lin the 800/100 
group and 2.6 and 0.45 mg/L in the 400/400 group. The most frequently found side 
effects were nausea and vomiting, which occurred in 22. l % and 34.9% of the patients 
in the 800/100 and the 400/400 groups, respectively. Viral load data were analyzed for 
patients who switched from 800-mg indinavir three times daily to one of the indinavir 
+ ritonavir twice daily regimens. At the time of switch 63% (800/100 group) and 60% 
(400/400 group) had an undetectable viral load and this increased to 77% and 70%, 
respectively, during follow-up. Patients who switched to the 400/400 group discon-
tinued treatment more frequently than patients who switched to the 800/100 group 
(70% vs. 26%, p .008). 
Conclusions: lndinavir + ritonavir regimens show improved pharmacokinetic prop-
erties, allowing twice-daily dosing with food. Clinical data suggest that safety and 
efficacy is at least as good as with indinavir three-times-daily regimens without rito-
navir. Prospective, comparative trials are needed to properly assess the role in HIV 
therapy of these twice-daily indinavir + ritonavir regimens. 
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Indinavir is one of the most widely used protease in-
hibitors. The popularity of this drug can be explained by 
its well-documented clinical efficacy, which has been 
reported to last at least 3 years (1), its relatively benign 
toxicity profile (2,3), and its mild (relative to that of 
ritonavir) drug-drug interaction profile (4). 
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In contrast to these favorable characteristics, however, 
use of indinavir has also some disadvantages. The drug 
should be taken with a low-fat, low-calorie meal or on an 
empty stomach, which means 1 hour before or 2 hours 
after a meal. Because indinavir is dosed three times daily, 
patients must deal with arranging meals and drug intake 
during a large part of the day. From a pharmacokinetic 
perspective, indinavir has also some unfavorable character-
istics. Due to good absorption, especially when indinavir is 
ingested on an empty stomach, the plasma concentration 
increases rapidly, leading to high concentrations that may 
be related to nephrologic and urologic complications (5,6). 
Furthermore, due to extensive cytochrome P450-mediated 
metabolism, indinavir plasma concentrations decrease 
rapidly, resulting in trough concentrations that are only 2 
to 4 times higher than the 95% (IC95 ) inhibitory concen-
tration. Interpatient and intrapatient variability may re-
sult in trough concentrations that are even closer to the 
IC95, which has been associated with suboptimal viral 
suppression (7-9). The small difference between indina-
vir trough concentration and the IC95 necessitates strict 
adherence to the every-8-hours regimen. Intervals of >8 
hours between two doses and/or neglecting food require-
ments will result in exposure to suboptimal drug concen-
trations [i.e., <0.10 mg/L (7,8)], which may be associated 
with the emergence of drug resistance and, eventually, 
loss of antiviral effect. 
If it were possible to improve the pharmacokinetic 
profile of indinavir while maintaining its antiviral po-
tency and tolerability, this would be a welcome extension 
of today's antiretroviral therapeutic options. Combining 
indinavir with ritonavir is one way to improve the phar-
macokinetic profile of indinavir (10). Ritonavir inhibits 
cytochrome P450-mediated metabolism of indinavir (and 
other protease inhibitors), which makes it possible to 
administer indinavir twice daily with or without food 
(11, 12). Healthy volunteer studies have shown that there 
are two different dosing strategies to combine indinavir 
with ritonavir: 800-mg indinavir + low-dose (e.g., 100-
200 mg) ritonavir (12) or 400 mg ( 11) of both protease 
inhibitors. Although these regimens are becoming in-
creasingly popular in clinical practice, no systematic re-
view of the pharmacokinetics, safety, and efficacy in 
HIV-infected patients has been available so far. In this 
study, we have investigated the pharmacokinetics, safety, 
and efficacy of both twice-daily indinavir + ritonavir 
combinations. 
METHODS 
Patient Selection 
All physicians in the Netherlands who treat HIV-infected patients 
were offered the possibility of sending samples for drug concentration 
monitoring. Physicians were instructed to record the following infor-
mation on the sample application form: reason for requesting drug 
concentration measurement (suspicion of drug interaction, suboptimal 
therapy, toxicity or noncompliance, routine control), date, dosage of 
antiretroviral drugs, time of blood sampling, time of last drug ingestion, 
and use of concomitant medications. 
Information on the sample application forms was entered in a Mi-
crosoft Access 2.0 database (Microsoft, Redmond, WA, U.S.A.) be-
tween spring 1997 and July 1999. At the time of analysis, July 1999, 
the database contained data on > 1,000 patients who were using indi-
navir as part of their antiretroviral regimen. For the purpose of this 
study, data were extracted from the database for patients who had been 
prescribed both indinavir and ritonavir as part of their antiretroviral 
regimen. 
Drug Concentration Measurement and 
Pharmacokinetic Analysis 
Indinavir plasma concentrations were measured according to the 
methods described elsewhere (13,14). Ritonavir plasma concentrations 
were measured by the method of Hugen et al. (14). Individual drug 
concentrations at each specific sampling time postingestion were en-
tered into a pharmacokinetic curve-fitting program (Kinfit, Mediware, 
J.H. Proost, Groningen, The Netherlands) ( 15). The appropriate phar-
macokinetic model was selected by using Akaike' s information crite-
rion and the average population pharmacokinetic curve was drawn. 
Safety and Efficacy Measurements 
A brief questionnaire was sent to various hospitals to collect infor-
mation on previous use of antiretroviral drugs and the reason to switch 
to an indinavir + ritonavir combination. Data on viral load, the occur-
rence of side effects, and lipid concentration measurements before and 
after switching to an indinavir + ritonavir combination were also re-
quested. Physicians who had submitted samples for measuring indina-
vir concentrations were asked to complete these questionnaires. 
RESULTS 
Pharmacokinetic Data 
In all, 132 patients were identified, 100 of whom used 
indinavir 800 mg + low-dose ritonavir ( 100 mg) twice 
daily (800/100 group) and 32 who used both drugs in a 
dose of 400 mg twice daily (400/400 group). A total 225 
samples were analyzed: 177 from the 800/ 100 group; 48 
from the 400/400 group. Samples were taken at random 
times postingestion with no specific cluster of time-
points, except a relatively high number of trough 
samples. After entering the individual plasma concentra-
tions of indinavir and ritonavir into the Kinfit program, 
pharmacokinetic parameters were calculated (Table 1). 
In all cases, a two-compartment model with a lag-time 
best fit the data. The fitted average pharmacokinetic 
curves of indinavir and ritonavir in both dosing regimens 
are shown in Figures I and 2. Analysis of the trough 
concentrations of indinavir and ritonavir in patients using 
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TABLE 1. Pharmacokinetic paramaters of indinavir and ritonavir 
as calculated by the Kinfit program 
Regimen 800/100 400/400 
Drug Indinavir Ritonavir lndinavir Ritonavir 
cmax (mg/L) 8.9 2.2 3.3 9.1 
T max (hr) 1.4 3.0 3.4 3.3 
AUC0-, 2 h, (mg/L x hr) 46.6 17.4 21.0 57.2 
Cm,n (mg/L) 1.3 0.53 0.31 1.5 
CL/F (L/hr) 16.3 5.3 17.9 6.6 
Vd/F (L) 80.7 24.4 44.3 16.1 
Cmax• maximum concentration; T max• time of maximum concentra-
tion; CL/F; clearance; Vd/F, volume of distribution. 
800/100 combination revealed a remarkably strong cor-
relation between these two parameters. The fitted corre-
lation has the following equation: [indinavir trough con-
centration in mg/L] = 2.01 x [ritonavir trough concen-
tration in mg/L] + 0.07; r = 0.89; p < .01. The number 
of trough samples in the 400/400 group was too small to 
repeat this analysis in this group of patients. 
Several patients who suffered from toxicity while us-
ing the 800/100 regimen had a dose modification to 600-
mg or 400-mg indinavir twice daily + 100-mg ritonavir 
twice daily. The peak and trough drug concentrations 
that were measured while these patients followed the 
modified regimen are listed in Table 2. In this subgroup 
of selected patients, the modified drug combination regi-
men resulted in drug concentrations that were compa-
rable with those observed on average in the 800/100 
group. 
Safety and Efficacy Data 
In all, 132 questionnaires were sent to participating 
physicians. The response rate to the questionnaire was 
72% in the 400/400 group and 77% in the 800/100 group. 
Data for the 800/100 group and the 400/400 group are 
presented separately. 
800/100 Group 
More than half of the patients (56%) had used 800-mg 
indinavir three times daily before starting 800/100 twice 
daily. Other regimens included combinations without in-
dinavir (17%), 1200-mg indinavir twice daily (12%), no 
therapy (10% ), or the 400/400 indinavir + ritonavir com-
bination (3% ). The reasons to start 800/100 twice daily 
were: a less complex regimen (26% ), a low indinavir 
plasma level (26% ), a high viral load (12% ), side effects 
(10%), drug interactions (4%) or not specified (22%). 
Side effects that were reported in more than 4% are 
listed in Table 3. Nausea and vomiting were the most 
frequently reported side effects, followed by nephrotox-
icity (renal stones, hematuria, crystalluria), lipodystro-
phy syndrome, skin reactions, and hyperbilirubinemia. 
Analysis of plasma cholesterol concentrations measured 
before and after starting 800/100 showed that the median 
cholesterol concentration increased from 5.2 (interquar-
tile ratio [IQR], 4.5-6.2) mmol/L to 5.7 (IQR, 4.9-7.4) 
mmol/L. Median triglyceride concentrations increased 
from 2.5 (IQR, 1.4-4.0) mmol/L to 3.1 (IQR, 1.9-4.4) 
mmol/L. Most physicians noted on the questionnaire that 
they did not know whether the patient was fasting, so 
these data must be considered as nonfasting results. 
Because most patients had been using 800-mg indina-
vir three times daily before switching to 800/100, and the 
other patients represent a rather heterogenous group 
(treatment-naive and nonnaive; indinavir-experienced 
and nonexperienced, and the like), it was decided to per-
form the viral load analysis only in those 43 patients who 
switched from 800-mg indinavir three times daily to the 
800/100 regimen. The median follow-up of these patients 
on 800/100 was 5 months (range, 1-13 months). Of the 
43 patients, 11 (26%) had stopped taking the indinavir + 
ritonavir combination at the time of analysis; in 10 of 
these 11 patients, side effects were the cause, while in 1 
case no cause was specified. 
Viral load data at baseline (i.e., before switching regi-
mens) and at the end of follow-up were available for 41 
patients (the other 2 patients had HIV-2 infection). Me-
dian viral load in these patients before the switch was 
<400 copies/ml, with 26 of these 41 patients (63%) hav-
ing a viral load below the limit of detection (which var-
ied from 5 to 400 copies/ml, depending on the assay used 
in each given hospital). During follow-up, the proportion 
of patients with an undetectable viral load increased from 
63% to 78% (intention-to-treat analysis) or 77% (on-
treatment analysis). Of the 26 patients with an undetect-
able viral load before switch, 24 (92%) also had an un-
detectable viral load during follow-up, whereas of the 15 
patients with a detectable viral load before switching, 8 
(53%) became undetectable after the switch. 
400/400 Group 
The largest group of patients ( 44%) had taken 800-mg 
indinavir three times daily before starting the 400/400 
regimen. Other regimens included combinations without 
indinavir (30% ), no therapy (17%) or the 800/100 indi-
navir + ritonavir combination (9% ). The reasons to start 
400/400 were: a less complex regimen (43%), a high 
viral load (26% ), side effects (17% ), a low indinavir 
plasma level ( 4% ), or not specified (9% ). 
Side effects that were reported in more than 4% are 
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FIG. 1. Fitted pharmacokinetic curves of indinavir when administered with ritonavir. 
listed in Table 3. As with the group receiving 800/100, 
nausea and vomiting were the most frequently reported 
side effects, followed by nephrotoxicity (renal stones, 
hematuria, crystalluria), diarrhea, and lipodystrophy. 
Analysis of plasma cholesterol concentrations measured 
before and after starting the 400/400 regimen showed 
that the median cholesterol concentration increased from 
5.2 (IQR, 4.2-5.8) mmol/L to 5.7 (IQR, 5.4-6.6) mmol/L. 
Median triglyceride concentrations increased from 2.6 
(IQR, 1.3-3.7) mmol/L to 3.1 (IQR, 1.8-4.5) mmol/L. 
Again, most physicians noted on the questionnaire that 
they did not know whether the patient was fasting. 
Because the largest part of the patients had been taking 
800-mg indinavir three times daily before switching to 
400/400, and to make a comparison with the 800/100 
group, viral load analysis was only performed in the 10 
patients who switched from 800-mg indinavir three times 
daily to 400/400 twice daily. The median follow-up of 
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FIG. 2. Fitted pharmacokinetic curves of ritonavir when administered with indinavir. 
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TABLE 2. Dosage modifications (800/100 group only) 
lndinavir Ritonavir 
concentration concentration 
Dose N (mg/L) (mg/L) 
Peak concentration 400/100 twice daily 2 4.9 ± 1.7 2.3 ± 1.1 
600/100 twice daily 2 5.8 ± 0.8 2.2 ± 0.2 
800/100 twice daily 86 7.6 ± 3.9 2.2 ± 1.7 
Trough concentration 400/100 twice daily 5 1.2 ±0.5 0.74 ± 0.36 
600/100 twice daily 7 1.4 ±0.5 0.64 ± 0. 18 
800/100 twice daily 63 1.2 ± I.I 0.55 ± 0.48 
these patients was 7 months (range, 1-14 months). Seven 
patients (70%) had stopped taking the indinavir + rito-
navir combination at the time of data analysis. Side ef-
fects were the reason given in 4 patients, 2 others stopped 
because of noncompliance or myocardial infarction, and 
no reason for discontinuation was specified for I patient. 
The median viral load before switch was <400 copies/ml, 
with 6 patients (60%) having a viral load below the limit 
of detection. During follow-up, the proportion of patients 
with an undetectable viral load increased from 60% to 
70% (intention-to-treat analysis) or 100% (on-treatment 
analysis). All patients with an undetectable viral load 
before switching continued to have undetectable viral 
loads. 
DISCUSSION 
The first clinical data on combining ritonavir + indi-
navir were reported in 1997 at the 36th Interscience Con-
ference on Antimicrobial Agents and Chemotherapy 
(ICAAC) in Toronto and published I year later (11). 
However, since then, only limited data have become 
available, despite widespread use of the combination in 
clinical practice. Until now, the pharmacokinetics of in-
dinavir + ritonavir when both are given in a 400-mg dose 
twice daily have only been described in healthy volun-
teers (11, 12). Furthermore, toxicity and efficacy data of 
indinavir + ritonavir regimens in HIV-infected patients 
have only been presented in abstract form ( 16-19), and 
these studies usually involved only small numbers of 
patients. 
In the healthy volunteer studies conducted by both 
Merck (12) and Abbott (11), it was demonstrated that 
indinavir can be given twice daily with food when com-
bined with 100- to 400-mg ritonavir. The indinavir + 
ritonavir combination is more convenient for patients 
than the registered regimen that requires the intake of 
indinavir (without ritonavir) on an empty stomach or 
with a light meal every 8 hours. The healthy volunteer 
studies also showed that total exposure to indinavir does 
not differ when both drugs are given on an empty stom-
ach or with food, so this indicates that indinavir + rito-
navir represents the first dual PI combination that can be 
administered without food restrictions. It may be advis-
able, however, to take indinavir + ritonavir with food 
because this results in blunting of the peak indinavir 
concentration (see following discussion) (11,12). Al-
though it is clear from Figure 1 that both twice daily 
regimens of indinavir + ritonavir result in improved 
pharmacokinetics of indinavir compared with the 800-
mg three-times-daily regimen of indinavir without rito-
navir, the two twice-daily regimens are not interchange-
able (11,12). The 800/100 regimen leads to similar peak 
concentrations of indinavir as is the situation with the 
800-mg three-times-daily regimen of indinavir without 
ritonavir, although trough concentrations are approxi-
mately tenfold higher. These data are in agreement with 
those from the healthy volunteer study (12) and the 6 
patients reported by Van Heeswijk et al. (20). The indi-
navir peak concentrations in the 400/400 regimen are 
substantially lower than with either of the two other regi-
mens, whereas trough concentrations fall somewhere be-
tween those obtained with the 800-mg three times daily 
and the 800/100 twice daily regimens. These data are in 
accordance with the healthy volunteer data (11 ). The 
implications of these differences have been the subject of 
much debate at recent international conferences. Most 
attention has focused on the differences in peak indinavir 
concentrations between the two twice-daily regimens be-
cause the development of nephrotoxicity, caused by pre-
cipitation of indinavir base in the kidneys, may be related 
to the height of the indinavir concentration in plasma (5). 
Given the values of peak indinavir concentration in this 
study, it can be expected that the incidence of nephro-
toxicity in the 800/100 twice-daily regimen will equal 
the incidence in patients using indinavir 800 mg three 
times daily without ritonavir, whereas incidence in the 
400/400 regimen will probably be lower. This is in 
agreement with the reported incidences of nephrotoxicity 
shown in Table 3. Less attention has been paid to pos-
sible differences in indinavir trough concentrations be-
tween the various regimens. Our data show that indinavir 
trough concentrations in the 800/100 twice daily regimen 
are substantially higher than observed in either of the 
TABLE 3. Side effects 
Regimen 
N 
Nausea, vomiting 
Renal stones, hematuria, crystalluria 
Lipodystrophy 
Hyperbilirubinemia 
Diarrhea 
Skin reaction 
800/100 
77 
22.1% 
14.3% 
13.0% 
Jl.7% 
5.2% 
13.0% 
400/400 
23 
34.9% 
8.7% 
4.3% 
4.3% 
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other regimens (Table 1, Fig. 2). This may allow the 
800/100 twice-daily regimen to suppress HIV with mod-
erately decreased susceptibility to indinavir (i.e., a 4-fold 
to 10-fold increase in IC95) because of the 10-fold higher 
indinavir trough concentrations. Trough concentrations 
of indinavir after intake of the 400/400 regimen may not 
be sufficiently high enough to overcome such an increase 
in IC95 . Because of the almost 100% cross-resistance 
between indinavir and ritonavir (21), it seems unlikely 
that ritonavir in the 400/400 combination will have much 
virologic effect on virus with decreased susceptibility to 
either drug. 
The interpretation of the reported side effects is com-
plicated. First, this study was not randomized and pa-
tients may not have been similar while starting one of the 
twice-daily regimens. Second, the data collection may be 
unreliable because physicians may remember the most 
recent or the most impressive side effects most clearly. 
Third, some side effects may result from incorrect use of 
the drugs. For example, the first patients who started on 
the 800/100 regimen did so by taking the drugs on an 
empty stomach because no information on influence of 
food on this regimen was known at that time. This may 
have led to higher peak concentrations of indinavir than 
after eating because food blunts the peak concentration 
as a result of delayed absorption ( 11, 12). Another prob-
lem in the evaluation of side effects in this study may be 
that such side effects were already present with the pre-
vious regimen (e.g., lipodystrophy syndrome) and are not 
likely to be specifically related to the indinavir + ritona-
vir regimen. Therefore, no definitive conclusions can be 
drawn concerning any differences in toxicities between 
the two twice-daily regimens. 
Given the uncertainty of reporting side effects in this 
study, the following observations ought be noted. Nausea 
is a well known side effect of both indinavir and ritona-
vir, so it is not surprising that this side effect was re-
ported most frequently in the questionnaires. The higher 
incidence of nephrotoxicity (defined as kidney stones, 
hematuria, or crystalluria) in the 800/100 regimen when 
compared with the 400/400 regimen is in agreement with 
the already discussed differences in indinavir peak con-
centrations. It must also be noted, however, that the in-
cidence of nephrotoxicity in the 400/400 regimen is not 
zero in this study, in contrast to the data reported by 
Workman et al. (22). Padberg et al. (23) recently reported 
a 12% incidence of elevated serum creatinine levels in 
patients using 400-mg indinavir + 400-mg ritonavir 
twice daily. A 32% incidence in nephrotoxicity was re-
ported by O'Brien et al. (16), but they were using a 
combination of 800-mg indinavir + 200-mg ritonavir, 
which leads to higher peak concentrations of indinavir 
than with 800/100 (12). Furthermore, their patients were 
suffering from an extremely hot summer in Texas at the 
time the data were being collected (W. O'Brien, oral 
communication, April 1999). 
Recent data from Youle et al. (24) suggest that, when 
combined with indinavir, higher ritonavir doses lead to a 
more pronounced risk of lipid abnormalities than with 
lower ritonavir doses. Given the uncertain long-term ef-
fects of increased lipid concentrations, minimal changes 
in lipid concentrations are desirable, which suggests a 
preference for the 800/100 regimen over the 400/400 
regimen. Our data do not confirm these observations of 
Youle et al. Nonstandardized (i.e., nonfasting) measure-
ments of lipids in our study and small numbers in the 
various regimens in Youle's study (there were only 2 
patients in their 800/100 group) may explain the differ-
ence in the findings. 
This study is the first to report on the virologic effi-
cacy of the 800/100 regimen. In the subset of patients 
who switched from 800-mg indinavir three times daily to 
the 800/100 regimen, almost all patients who had an 
undetectable viral load remained undetectable, whereas a 
significant proportion of patients with a detectable viral 
load became undetectable. This indicates that the antivi-
ral activity of the 800/100 combination is at least similar 
to regimens containing 800-mg indinavir three times 
daily. Although not specified in the questionnaire, most 
physicians reported that nucleosides were not changed 
when adding low-dose ritonavir. Approximately 25% of 
the patients in the 800/100 group discontinued this regi-
men, showing that tolerability issues may compromise 
the antiviral activity. Most physicians were not aware 
that dose modification to 600/100 or even 400/100 is 
possible. All patients who had a dose modification be-
cause of toxicity from the 800/100 regimen had adequate 
trough indinavir concentrations (Table 2) and demon-
strated sustained virologic response. Patients suffering 
from toxicity while using the 800/100 regimen are likely 
to represent a subpopulation of patients with greater than 
average increased exposure to indinavir, and they can 
benefit from dosage modifications. Because there were 
only 10 patients who switched from an 800-mg indinavir 
three times daily regimen to the 400/400 twice-daily 
regimen, it is difficult to compare the virologic potency 
and tolerability of this combination with the 800/100 
twice-daily regimen. Patients who switched to the 400/ 
400 group discontinued treatment more frequently than 
patients who switched to the 800/100 group (70% vs. 
26%, p = .008; using the two-sample proportion test). 
We have no experience in modifying the dose in the 
400/400 regimen. The observed intolerance may be 
partly due to the use of the liquid formulation of ritona-
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vir, because capsules were not available during most of 
the time during which this survey was conducted. The 
same phenomenon was observed in the study of Rock-
stroh et al. (19). Whether the discontinuation rate will be 
lower using ritonavir capsules instead of a liquid formu-
lation remains to be established. All patients who were 
able to tolerate the 400/400 regimen had a good virologic 
response (3 of 3 patients with an undetectable viral load 
in the on-treatment analysis), which is in agreement with 
the data from Rockstroh et al. (19) and Workman et al. 
(25). 
In conclusion, both the 800/100 and the 400/400 
twice-daily regimens showed improved pharmacokinetic 
properties when compared with regimens supplying 800-
mg indinavir three times daily without ritonavir. The 
virologic efficacy of both regimens appears to be at least 
similar to what is observed with 800-mg indinavir three 
times daily. The 800/100 regimen had a lower discon-
tinuation rate than the 400/400 regimen. Prospective, com-
parative trials are needed to properly assess the role in HIV 
therapy of these twice-daily indinavir + ritonavir regimens. 
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